echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 19,000 Real-World Study Englenet Reduces Hospitalization Risk of Heart Failure

    19,000 Real-World Study Englenet Reduces Hospitalization Risk of Heart Failure

    • Last Update: 2020-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the International Diabetes Alliance (IDF), the number of people with diabetes in China reached 114 million in 2017, and that number could rise to 151 million by 2040Type 2 diabetes is associated with large and microvascular complications, with about one-third of people with type 2 diabetes suffering from cardiovascular disease, which is the leading cause of death in people with type 2 diabetesheart failure is a carried, debilitating and potentially fatal diseaseThe patient's heart does not provide enough blood for the bodySymptoms of heart failure include difficulty breathing, swelling (most commonly feet, legs and feet), and fatigueIt can also lead to a significant decline in quality of life, in part because of limited physical activity and difficulties in performing typical daily activitiesGlobally, 60 million people are affected by heart failureThe prevalence of heart failure is expected to increase as the population agesAlthough heart failure is common in diabetic patients, about 50% of heart failure patients do not have diabetesDiabetics need drugs that reduce the risk of heart failure and prevent heart failureby inhibiting the reabsorption of glucose back into the blood stream of the main transporting protein SGLT2, Englenet reduces the reabsorption of glucose in the kidneys, allowing it to be excreted with urine, thus lowering glucose levels in the bloodThe mechanism of action of Engre net is independent of insulinIt was approved by the FDA in late 2016 to lower blood sugar in people with type 2 diabetes with cardiovascular disease and their risk of death from cardiovascular diseaseEMPRISE study, which aims to complement the results of the landmark EMPA-REG OUTCOME trial and provide further data supportThe EMPA-REG OUTCOME trial was conducted in 7,000 patients with combined cardiovascular disease with type 2 diabetes, adding engrestosin to standard treatments (sugar-lowering drugs and cardiovascular drugs, including blood pressure and cholesterol drugs)The primary endpoint is the time of the first cardiovascular death, non-fatal heart attack, or non-fatal strokeIn addition to placebo, Engrenet reduced the risk of hospitalization for heart failure in patients with combined type 2 diabetes cardiovascular disease by 35 percent EMPRISE study aims to analyze the effectiveness and safety of Engler Net in the real world In the process of the new drug market, the real world research position is very important Real-world studies often find problems not seen in clinical studies, especially with regard to drug side effects This mid-term analysis covered data on 19,000 people with type 2 diabetes, regardless of whether they have cardiovascular disease or not Compared to DPP-4 inhibitors and GLP-1 receptor agonists, Engel's net energy significantly reduced the risk of hospitalization for heart failure by 41% and 17%, respectively In reducing the risk of non-fatal atherosclerosis cardiovascular events, Englinet's net performance was similar to that of DPP-4 inhibitors and GLP-1 receptor agonists Dr Sherry Martin, Vice President of Global Medical Affairs, Lilly, said, "Lilly is pleased to see that the three-year data from EMPRISE continues to complement the results of the EMPA-REG OUTCOME trial The data from the real world is part of Engler's extensive and comprehensive clinical development program, including heart failure, which is the focus of this study Engler's net development program aims to improve patient health It may fill the treatment gap for patients with cardiopulmonary metabolic disease " References: Interim analysis from EMPRISE real-world show empagliflozzin yn studyed risk of hospital for heart for heart lying with DPP-4s and GLP-1 stateenists Retrieved Nov 18, 2019, from https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.